omniture
DAEWOONG PHARMACEUTICAL

Latest News

Daewoong Pharmaceutical Announce Publication of Phase 3 Study of 'Envlo', a New Treatment for Diabetes, in the International SCIE Journal

SEOUL, South Korea, April 24, 2023 /PRNewswire/ -- The research results of Daewoong Pharmaceutical'...

2023-04-24 14:53 3795

Daewoong Pharmaceutical and Sygnature Discovery announce drug discovery research collaboration

- 'Daewoong Pharmaceutical enters research collaboration to discover a novel small molecule to tar...

2023-04-18 17:16 4427

Daewoong Pharmaceutical's Envlo to enter the global market in full swing with filing for product license in three ASEAN countries

* Submitted an NDA to Indonesia, Philippines and Thailand * Signed the export contract in Brazil...

2023-03-22 21:20 4590

Daewoong Pharmaceutical Reaches Sales of KRW 1.16 Trillion in 2022, Fexuclue Leads The Highest Revenue

- Hitting a record high sale with business profits of KRW 106 billion and net profits ofKRW 80.1 bi...

2023-02-20 12:29 2870

Daewoong Pharmaceutical begins the first administration of the Bersiporocin, new treatment for idiopathic pulmonary fibrosis, as Phase II clinical trial

- Evaluation of Bersiporocin's safety and efficacy against a total of 102 patients over 24 weeks -...

2023-02-06 13:00 2532

Daewoong enters exclusive licensing agreement with CS Pharmaceuticals for Bersiporocin in Idiopathic Pulmonary Fibrosis in the Greater China Region

* Daewoong Pharmaceutical to receive up to $76M upfront and development milestone payment plus a...

2023-01-31 14:43 5816

Daewoong Pharmaceutical submitted NDA for its global new drug Fexuclue in 11 countries, only 1 year after approval in Korea

"Expected to change GERD drug market landscape" * Application for product approval of Fexuclue, ...

2023-01-26 09:14 3721

Daewoong Pharmaceutical announces success in developing a new antidiabetic medication and its aims to enter the market in over 50 countries by 2030

* Delivers new drug for two consecutive years by obtaining product license on "Envlo", Korea's 36...

2022-12-06 20:00 2321

Daewoong Pharmaceutical Surpasses KRW 300 Billion in Q3 Revenue as Nabota Sales Grew by 93%, Leading Overall Growth in Revenue

* Nabota exports grew significantly, achieving a 93.3% growth YOY, and overall revenue topsKRW 40...

2022-11-15 20:00 2356

Daewoong Pharmaceutical Presents Phase 3 Clinical Trial Results of New Diabetes Treatment 'Enavogliflozin' and Roadmap to Enter 50 Countries by 2030

* Highly anticipated to be an effective therapeutic for its excellent efficacies in reducing bloo...

2022-11-02 09:00 2934

CGBio Signing a North America Out-license Contract on "Novosis rhBMP-2," a Bone Substitute with Orthofix, USA

* Embarking on a successful journey of exporting its home-grown product technology toNorth Americ...

2022-08-04 21:00 3439

Daewoong Pharmaceutical Co., Ltd. revs up the growth engine for Nabota, achieving the highest quarterly performance ever

-  Daewoong Pharmaceutical Co., Ltd. achieved 293.8 billion won in sales and 33.6 billion won in op...

2022-07-28 21:00 3477

Daewoong Pharmaceutical Gets First Korean US FDA Fast-Track for New Idiopathic Pulmonary Fibrosis Drug

* US Food and Drug Administration (FDA) fast-tracks idiopathic pulmonary fibrosis treatment DWN1...

2022-07-20 21:00 2240

Daewoong Pharmaceutical begins multinational phase 2 clinical trial for DWN12088, a new drug for idiopathic pulmonary fibrosis

- U.S. Food and Drug Administration (FDA) approved the IND for the phase 2 clinical trial for patie...

2022-06-24 21:00 4257

Daewoong Pharmaceutical announced first-quarter 2022 results

- Marked sales of KRW 272.2 billion and operating profit of KRW 26.8 billion - Reported record-high...

2022-05-05 21:00 2736

HanAll Biopharma and Daewoong Pharmaceutical Invest in Turn Biotechnologies to Expand Growth Initiative

* HanAll Biopharma and Daewoong Pharmaceutical invest in the broad potential of Turn Biotechnolog...

2022-04-13 08:00 2332

/DISREGARD RELEASE: HanAll Biopharma and Daewoong Pharmaceutical/

We are advised by HanAll Biopharma and Daewoong Pharmaceutical that journalists and other readers s...

2022-04-12 15:34 2653

Daewoong Pharmaceutical submitted NDA for its global new drug Fexuclue Tablets to the Philippines

- From Last February to mid-March, NDA has been submitted to each country sequentially - Daewoong ...

2022-03-29 09:00 3609

Daewoong Pharmaceutical Announces Successful Phase 3 Topline Results for New Antidiabetic Drug's Triple Combination Therapy

SEOUL, South Korea, Feb. 25, 2022 /PRNewswire/ -- Daewoong Pharmaceutical (Daewoong) announced the ...

2022-02-25 22:00 3955

HanAll Biopharma Appoints Almira Chabi as Chief Medical Officer and Chief Development Officer

SEOUL, South Korea, Feb. 21, 2022 /PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS) announced today...

2022-02-21 22:00 2644
123